Increased mucosal IL-12 expression is associated with relapse of ulcerative colitis.
IL-12
IL-23
Rectal mucosa
Relapse
Ulcerative colitis
Journal
BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547
Informations de publication
Date de publication:
17 Mar 2021
17 Mar 2021
Historique:
received:
04
01
2021
accepted:
24
02
2021
entrez:
18
3
2021
pubmed:
19
3
2021
medline:
15
5
2021
Statut:
epublish
Résumé
The role of IL-12/23 in the pathogenesis of ulcerative colitis (UC) is unclear. We analyzed mucosal IL-12/23 expression and its relationship with endoscopic severity, histological activity, and UC relapse. Rectal biopsies were collected from 70 UC patients with clinical remission. IL-12, IL-23, IFN-γ, IL-17A, and IL-17F mRNA expression was measured by real-time PCR. Endoscopic severity and histological activity were evaluated using the Mayo endoscopic subscore (MES) and the Geboes score, respectively. The longest follow-up period was 51 months. Thirty-four patients relapsed during the study period. Samples from these subsequently relapsed patients formed the "relapse" group, while those from patients that did not relapse formed the "remission" group. IL-12 (P = 0.0003) and IL-23 (P = 0.014) mRNA expression was significantly higher in the relapse than the remission group. Expression of IL-23 (P = 0.015) but not IL-12 (P = 0.374) was correlated with MES. However, in patients with an MES of 0 and 1, IL-12 expression was statistically higher in the relapse than the remission group (P = 0.0015, P = 0.0342). IL-12 and IL-23 expression did not vary significantly between histologically active and inactive mucosa; both were higher in histologically inactive patients in the remission group (IL-12: P = 0.0002, IL-23: P = 0.046). Rectal IL-12 and IL-23 expression was elevated in the relapse group, but IL-12 was more strongly associated with UC relapse, irrespective of endoscopic severity and histological activity. Mucosal IL-12 was elevated in patients with deep mucosal healing. Our results suggest an important role of IL-12 in UC pathogenesis and the molecular mechanism of UC relapse.
Sections du résumé
BACKGROUND
BACKGROUND
The role of IL-12/23 in the pathogenesis of ulcerative colitis (UC) is unclear. We analyzed mucosal IL-12/23 expression and its relationship with endoscopic severity, histological activity, and UC relapse.
METHODS
METHODS
Rectal biopsies were collected from 70 UC patients with clinical remission. IL-12, IL-23, IFN-γ, IL-17A, and IL-17F mRNA expression was measured by real-time PCR. Endoscopic severity and histological activity were evaluated using the Mayo endoscopic subscore (MES) and the Geboes score, respectively.
RESULTS
RESULTS
The longest follow-up period was 51 months. Thirty-four patients relapsed during the study period. Samples from these subsequently relapsed patients formed the "relapse" group, while those from patients that did not relapse formed the "remission" group. IL-12 (P = 0.0003) and IL-23 (P = 0.014) mRNA expression was significantly higher in the relapse than the remission group. Expression of IL-23 (P = 0.015) but not IL-12 (P = 0.374) was correlated with MES. However, in patients with an MES of 0 and 1, IL-12 expression was statistically higher in the relapse than the remission group (P = 0.0015, P = 0.0342). IL-12 and IL-23 expression did not vary significantly between histologically active and inactive mucosa; both were higher in histologically inactive patients in the remission group (IL-12: P = 0.0002, IL-23: P = 0.046).
CONCLUSIONS
CONCLUSIONS
Rectal IL-12 and IL-23 expression was elevated in the relapse group, but IL-12 was more strongly associated with UC relapse, irrespective of endoscopic severity and histological activity. Mucosal IL-12 was elevated in patients with deep mucosal healing. Our results suggest an important role of IL-12 in UC pathogenesis and the molecular mechanism of UC relapse.
Identifiants
pubmed: 33730998
doi: 10.1186/s12876-021-01709-5
pii: 10.1186/s12876-021-01709-5
pmc: PMC7968323
doi:
Substances chimiques
Interleukin-12
187348-17-0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
122Références
Inflamm Bowel Dis. 1998 Nov;4(4):328-9
pubmed: 9836088
Nature. 1996 Jul 11;382(6587):171-4
pubmed: 8700208
Cureus. 2017 Apr 19;9(4):e1177
pubmed: 28533995
Clin Transl Gastroenterol. 2016 Jan 07;7:e135
pubmed: 26741065
Gastroenterology. 2011 Oct;141(4):1194-201
pubmed: 21723220
Aliment Pharmacol Ther. 2013 May;37(10):998-1004
pubmed: 23521659
Nat Immunol. 2012 Jul 19;13(8):722-8
pubmed: 22814351
J Immunol. 1995 May 15;154(10):5071-9
pubmed: 7730613
Am J Gastroenterol. 2016 May;111(5):685-90
pubmed: 26977756
Gut. 2000 Sep;47(3):404-9
pubmed: 10940279
Nat Rev Immunol. 2003 Feb;3(2):133-46
pubmed: 12563297
Nat Rev Gastroenterol Hepatol. 2019 Mar;16(3):185-196
pubmed: 30478416
World J Gastroenterol. 2009 May 7;15(17):2067-73
pubmed: 19418577
N Engl J Med. 2016 Nov 17;375(20):1946-1960
pubmed: 27959607
Aliment Pharmacol Ther. 2020 Jun;51(11):1039-1046
pubmed: 32291786
N Engl J Med. 1994 Jun 30;330(26):1841-5
pubmed: 8196726
Scand J Gastroenterol. 2020 Feb;55(2):139-147
pubmed: 31918598
Cytokine. 2015 Oct;75(2):249-55
pubmed: 25796985
J Exp Med. 1989 Sep 1;170(3):827-45
pubmed: 2504877
N Engl J Med. 2019 Sep 26;381(13):1201-1214
pubmed: 31553833
Am J Physiol Gastrointest Liver Physiol. 2012 May 15;302(10):G1163-70
pubmed: 22421620
Gut. 2016 Mar;65(3):408-14
pubmed: 25986946
Inflamm Bowel Dis. 2005 Jun;11(6):589-96
pubmed: 15905707
J Crohns Colitis. 2016 Jan;10(1):13-9
pubmed: 26351390
Inflamm Bowel Dis. 2019 May 4;25(6):1019-1027
pubmed: 30668727
J Crohns Colitis. 2017 Aug 1;11(8):963-969
pubmed: 28333209
J Crohns Colitis. 2020 Jan 1;14(1):79-95
pubmed: 31206576